IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v20y2023i5p4545-d1087342.html
   My bibliography  Save this article

Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan

Author

Listed:
  • Mitsunobu Otsuru

    (Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8588, Japan)

  • Souichi Yanamoto

    (Department of Oral Oncology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan)

  • Shin-ichi Yamada

    (Department of Dentistry and Oral Surgery, Shinshu University School of Medicine, Matsumoto 390-8621, Japan
    Department of Oral and Maxillofacial Surgery, Faculty of Medicine, University of Toyama, Toyama 930-8555, Japan)

  • Kohichi Nakashiro

    (Department of Oral and Maxillofacial Surgery, Ehime University Graduate School of Medicine, Ehime 791-0295, Japan)

  • Yosuke Harazono

    (Department of Maxillofacial Surgery, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8549, Japan)

  • Tomoyuki Kohgo

    (Department of Oral and Maxillofacial Surgery, Keiyukai Sapporo Hospital, Sapporo 003-0026, Japan)

  • Moriyoshi Nakamura

    (Dental and Oral Medical Center, Kurume University School of Medicine, Kurume 830-0011, Japan)

  • Takeshi Nomura

    (Oral Cancer Center, Tokyo Dental College, Chiba 272-8513, Japan)

  • Atsushi Kasamatsu

    (Department of Oral Science, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan)

  • Susumu Tanaka

    (The 1st Department of Oral and Maxillofacial Surgery, Graduate School of Dentistry, Osaka University, Osaka 565-0871, Japan)

  • Tadaaki Kirita

    (Department of Oral and Maxillofacial Surgery, Nara Medical University, Nara 634-8521, Japan)

  • Mitomu Kioi

    (Department of Oral and Maxillofacial Surgery, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan)

  • Masaru Ogawa

    (Department of Oral and Maxillofacial Surgery and Plastic Surgery, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan)

  • Masashi Sasaki

    (Department of Oral and Maxillofacial Surgery, Tokai University School of Medicine, Isehara 259-1193, Japan)

  • Yoshihide Ota

    (Department of Oral and Maxillofacial Surgery, Tokai University School of Medicine, Isehara 259-1193, Japan)

  • Masahiro Umeda

    (Department of Clinical Oral Oncology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki 852-8588, Japan)

Abstract

There are a few reports that focus on radiotherapy (RT) and cetuximab (CET) therapy exclusively for oral cancer. This retrospective study aimed to investigate the efficacy and safety of RT and CET therapy for locally advanced (LA) or recurrent/metastatic (R/M) oral squamous cell carcinoma (OSCC). Seventy-nine patients from 13 hospitals who underwent RT and CET therapy for LA or R/M OSCC between January 2013 and May 2015 were enrolled in the study. Response, overall survival (OS), disease-specific survival (DSS), and adverse events were investigated. The completion rate was 62/79 (78.5%). The response rates in patients with LA and R/M OSCC were 69% and 37.8%, respectively. When only completed cases were examined, the response rates were 72.2% and 62.9%, respectively. The 1- and 2-year OS were 51.5% and 27.8%, respectively (median, 14 months), for patients with LA OSCC, and 41.5% and 11.9% (median, 10 months) for patients with R/M OSCC. The 1- and 2-year DSS were 61.8% and 33.4%, respectively (median, 17 months), for patients with LA OSCC, and 76.6% and 20.4% (median, 12 months) for patients with R/M OSCC. The most common adverse event was oral mucositis (60.8%), followed by dermatitis, acneiform rash, and paronychia. The completion rate was 85.7% in LA patients and 70.3% in R/M patients. The most common reason for noncompletion was an inadequate radiation dose due to worsening general conditions in R/M patients. Although the standard treatment for LA or R/M oral cancer is concomitant RT with high-dose cisplatin (CCRT) and the efficacy of RT and CET therapy for oral cancer is not considered to be as high as that for other head and neck cancers, it was thought that RT and CET therapy could be possible treatments for patients who cannot use high-dose cisplatin.

Suggested Citation

  • Mitsunobu Otsuru & Souichi Yanamoto & Shin-ichi Yamada & Kohichi Nakashiro & Yosuke Harazono & Tomoyuki Kohgo & Moriyoshi Nakamura & Takeshi Nomura & Atsushi Kasamatsu & Susumu Tanaka & Tadaaki Kirita, 2023. "Radiotherapy Plus Cetuximab for Squamous Cell Carcinoma of the Oral Cavity: A Multicenter Retrospective Study of 79 Patients in Japan," IJERPH, MDPI, vol. 20(5), pages 1-10, March.
  • Handle: RePEc:gam:jijerp:v:20:y:2023:i:5:p:4545-:d:1087342
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/20/5/4545/pdf
    Download Restriction: no

    File URL: https://www.mdpi.com/1660-4601/20/5/4545/
    Download Restriction: no
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:20:y:2023:i:5:p:4545-:d:1087342. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.